Redefining dermatomyositis: A description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features

Medicine (United States)

Volumn 93, Issue 24, 2014, Pages 318-332

  Troyanov, Yves ^a,b   Targoff, Ira N ^d   Payette, Marie Pier ^b   Raynauld, Jean Pierre ^b   Chartier, Suzanne ^c   Goulet, Jean Richard ^b   Bourré Tessier, Josiane ^b   Rich, Eric ^b   Grodzicky, Tamara ^b   Fritzler, Marvin J ^b,e   Joyal, France ^c   Koenig, Martial ^c   Senécal, Jean Luc ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Division of Rheumatology   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; JO 1 ANTIBODY; MI 2 ANTIBODY; MJ ANTIBODY; P155 ANTIBODY; PL 7 ANTIBODY; PM SCL ANTIBODY; PROTEIN A; U1RNP ANTIBODY; U5 RNP ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATROPHY; AUTOIMMUNE MYOSITIS; BONE BIOPSY; CALCINOSIS; CHRONICITY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MODIFIED BOHAN AND PETER CLASSIFICATION; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NEOPLASM; OVERLAP MYOSITIS; PAPULE; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; SERUM; SKELETAL MUSCLE; SURVIVAL; ADOLESCENT; BLOOD; DIFFERENTIAL DIAGNOSIS; EXANTHEMA; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SKIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATROPHY; AUTOANTIBODIES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; SKIN; YOUNG ADULT;

EID: 84926016157     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000222     Document Type: Article

References (19)

1. Arnett FC, Targoff IN, Minori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39:1507-1518.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (parts 1 and 2). Engl J Med N. 1975;292:344-407.
3. Chen Z, Cao M, Nieves Plana M, et al. Utility of anti-Melanoma Differentiation-Associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65: 1316-1324.
4. Fernandez C, Bardin N, De Paula AM, et al. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies. Study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013;92:15-24.
5. Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597-613.
6. Hall JC, Casciola-Rosen L, Samedy LA, et al.Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65:1307-1315.
7. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC International Workshop. trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337-345.
8. Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14:R50.
9. Klein RQ, Teal V, Taylor L, et al. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57:937-943.
10. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.
11. Isabelle C, Dabauvalle MC, Fritzler MJ, et al. An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes-description and long-term follow-up of the antinup syndrome. Arthritis Rheum. 2013;65:S880.
12. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68:472-478.
13. Oddis CV, Rider LG, Reed AM, et al. International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607-2615.
14. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011;23:595-604.
15. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81:154-167.
16. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10:333-340.
17. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine: two additional synthetases are antigenic in myositis. J Immunol. 1990;144:1737-1743.
18. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556-2564.
19. Troyanov Y, Targoff I, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap clinical features and autoantibodies: analysis of 100 French Canadian patients with myositis. Medicine (Baltimore). 2005;84:231-249.